Last reviewed · How we verify
NCT06612333: PEERS-MRND
Evaluation of the French Version of the PEERS Social Skills Training Program for Adolescents With Rare Neurodevelopmental Disorders
trial in Neurodevelopmental Disorders in 64 participants. Completed in 17 October 2025.
17 October 2025
Quick facts
| Lead sponsor | Imagine Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 1 May 2024 |
| Primary completion | 17 October 2025 |
| Estimated completion | 17 October 2025 |
| Sites | 1 location across France |
Conditions studied
- Neurodevelopmental Disorders — all drugs for Neurodevelopmental Disorders →
- Rare Diseases — all drugs for Rare Diseases →
Sponsor
Imagine Institute
Who can join
Adults 12 to 30, any sex, with Neurodevelopmental Disorders or Rare Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Adolescents and young adults with rare neurodevelopmental disorders are at risk of developing psychiatric pathologies during the transition to adulthood. Loneliness and lack of social relationships can lead to anxiety and depression in adolescents and young adults with rare neurodevelopmental disorders. Anxiety and depression are major risk factors for the transition to psychiatric symptoms in adulthood. The improvement of social skills and the positive evolution of social relationships in adolescents and young adults with rare neurodevelopmental disorders can lead to a reduction in the risk factors for anxiety and depression. It therefore seems essential to evaluate the evolution of social skills in this population of young adults under the care of the social skills program, PEERS, in France to assess the overall benefit of the program, particularly in this population of young people with rare neurodevelopmental disorders.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06612333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurodevelopmental Disorders
Currently open trials in the same condition.
- NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
- NCT06915480 — Reducing Missed Appointments · Phase 3 · recruiting
- NCT06807203 — Motor-voice Assessment in Infants (MAMI) · recruiting
- NCT05815095 — Early Detection and Referral for Autism and Neurodevelopmental Disorders at the Maternal and Child Protection Services · recruiting
- NCT06974136 — tES Modalities for the Treatment of ADHD · NA · recruiting
Other Imagine Institute trials
Trials by the same sponsor.
- NCT07313098 — Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvemen · not yet recruiting
- NCT07422454 — FACE.S-4-KIDS : A Deep Phenotyping Database of Craniofacial Anomalies During Development With 4 Pilot Projects · recruiting
- NCT06219421 — Automatic Phenotyping of Patients on 2D Photography · recruiting
- NCT06186856 — Epidemiological Data on Mast Cell Pathologies in France · recruiting
- NCT06380192 — Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06612333 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imagine Institute
- Last refreshed: 19 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06612333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing